Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATYR 
aTyr Pharma, Inc. (ATYR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ATYR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20.15
1 Year Target Price $20.15
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.91% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 590.86M USD | Price to earnings Ratio - | 1Y Target Price 20.15 |
Price to earnings Ratio - | 1Y Target Price 20.15 | ||
Volume (30-day avg) 11 | Beta 1.01 | 52 Weeks Range 1.67 - 7.29 | Updated Date 09/13/2025 |
52 Weeks Range 1.67 - 7.29 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.2% | Return on Equity (TTM) -85.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 523191403 | Price to Sales(TTM) 1147.59 |
Enterprise Value 523191403 | Price to Sales(TTM) 1147.59 | ||
Enterprise Value to Revenue 132.17 | Enterprise Value to EBITDA -0.81 | Shares Outstanding 97986600 | Shares Floating 95966150 |
Shares Outstanding 97986600 | Shares Floating 95966150 | ||
Percent Insiders 2.03 | Percent Institutions 68.66 |
Upturn AI SWOT
aTyr Pharma, Inc.
Company Overview
History and Background
aTyr Pharma, Inc. was founded in 2003. It is a biotherapeutics company engaged in the discovery and development of medicines based on novel biological pathways.
Core Business Areas
- Resolaris: Resolaris was a key product candidate for the treatment of facioscapulohumeral muscular dystrophy (FSHD). However, development was discontinued after Phase 3 trials failed.
- Efzofitimod: Efzofitimod (ATYR1923) is a selective modulator of neuropilin-2 (NRP2). It is currently in development for fibrotic lung diseases, including pulmonary sarcoidosis. It also was in development for COVID-19 related lung injury, but was not continued due to a lack of efficacy and changing treatment landscape.
Leadership and Structure
aTyr Pharma is led by a team of executives with experience in drug development and biotechnology. The organizational structure involves various departments including R&D, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- Efzofitimod: Efzofitimod (ATYR1923) is the company's lead clinical candidate being developed for interstitial lung disease and pulmonary sarcoidosis. Currently still in clinical trials, no revenue is generated from this product. Competitors would include companies developing therapies for pulmonary fibrosis such as Boehringer Ingelheim and Roche.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with many companies developing therapies for a wide range of diseases. Development focuses on pulmonary diseases, specifically pulmonary fibrosis and sarcoidosis.
Positioning
aTyr Pharma is a clinical-stage biopharmaceutical company focusing on a novel approach to treating fibrotic diseases. Its competitive advantage lies in its unique understanding of tRNA synthetase biology and the development of therapeutics modulating these pathways.
Total Addressable Market (TAM)
The TAM for pulmonary fibrosis and sarcoidosis is estimated to be billions of dollars. aTyr Pharma is aiming to capture a significant portion of this market by developing efzofitimod.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting tRNA synthetase biology
- Proprietary technology platform
- Lead clinical candidate with potential in multiple fibrotic diseases
- Experienced management team
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Small market capitalization
Opportunities
- Positive clinical trial results for efzofitimod
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other disease areas
- Potential for orphan drug designation for certain indications
Threats
- Clinical trial failures
- Competition from other companies developing therapies for fibrotic diseases
- Regulatory hurdles
- Patent expiration
Competitors and Market Share
Key Competitors
- GILD
- BMY
- ROG.SW
Competitive Landscape
aTyr Pharma competes with established pharmaceutical companies and other biotechnology firms developing therapies for fibrotic diseases. Its competitive advantage lies in its novel approach, while its disadvantage is its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: aTyr Pharma's historical growth has been characterized by advancing its pipeline through preclinical and clinical development.
Future Projections: Future growth depends on the successful development and commercialization of efzofitimod. Analyst estimates are highly speculative and based on projections of clinical trial success and market penetration.
Recent Initiatives: Recent initiatives include advancing efzofitimod in clinical trials for pulmonary sarcoidosis and other fibrotic lung diseases.
Summary
aTyr Pharma is a clinical-stage biopharmaceutical company with a novel therapeutic approach. Its success hinges on the positive results of its clinical trials for efzofitimod. The company faces challenges typical of development-stage biotechs, including high cash burn and regulatory hurdles. Positive clinical data and strategic partnerships are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Press Releases
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About aTyr Pharma, Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-05-07 | President, CEO & Director Dr. Sanjay S. Shukla M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://atyrpharma.com |
Full time employees 56 | Website https://atyrpharma.com | ||
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.